PCI Biotech $PCIB.OL testing breakout from yearlong downtrend
PCI Biotech Holding
PCIB
stock has been consolidating in a trading range below last years 30 NOK shareprice rights issue of NOK 360 million.
Positive market reaction to the latest quarterly report from the company, along with good coverage in magasines:
https://www.tu.no/artikler/selskapet-bruker-lys-i-behandling-av-kreft/472385 (norwegian language)
https://nordiclifescience.org/wp-content/public_html/2019/08/NL-nr-3-2019_150-dpi_uppslag.pdf (page 91-94)
At the moment, the stock is testing a breakout from the old trading range, and longs will be keen to see further conference or scientific journal coverage of the ongoing clinical programs for the companys FimaCHEM and FimaVACC products, as well as partnering deals for its FimaNAC product.
PCIB
stock has been consolidating in a trading range below last years 30 NOK shareprice rights issue of NOK 360 million. Positive market reaction to the latest quarterly report from the company, along with good coverage in magasines:
https://www.tu.no/artikler/selskapet-bruker-lys-i-behandling-av-kreft/472385 (norwegian language)
https://nordiclifescience.org/wp-content/public_html/2019/08/NL-nr-3-2019_150-dpi_uppslag.pdf (page 91-94)
At the moment, the stock is testing a breakout from the old trading range, and longs will be keen to see further conference or scientific journal coverage of the ongoing clinical programs for the companys FimaCHEM and FimaVACC products, as well as partnering deals for its FimaNAC product.
Trade ativo:
First test not looking to bright this monday, and stock is trading right above stop level
Trade fechado: stop atingido:
Stopped out of this trade, better luck next time!
